Skip to main
GPCR
GPCR logo

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics Inc. is positioned favorably in the biopharmaceutical sector due to its innovative approach to developing therapies targeting chronic diseases, particularly through its robust technology platform. The company’s clinical trials for orforglipron have demonstrated significant advancements, with improved gastrointestinal tolerability and a favorable safety profile, especially regarding liver and cardiovascular health, contributing to investor confidence. Furthermore, the positive market response, evidenced by a stock price increase of over 25% following favorable trial results in the ACHIEVE-1 study, underscores the potential for continued growth and value creation for the company.

Bears say

Structure Therapeutics Inc is currently facing significant financial challenges, with an estimated enterprise value (EV) of approximately $410 million and shares declining by 20% year-to-date, indicating a market underappreciation of its assets and potential. The company is expected to continue incurring net losses until at least commercialization and likely through the early launch phase, raising concerns about its financial sustainability and the necessity for a commercial partner given the competitive landscape in diabetes and obesity markets. Furthermore, while there are some promising results related to its lead candidate, aleniglipron, compared to existing therapies, the overall prospects remain overshadowed by ongoing financial risk and the pressures of meeting market expectations in a critical sector.

GPCR has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 7 analysts, GPCR has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.